Case reports: efalizumab-associated lymphoproliferative disease.

Satya Bommakanti, Amol Patil, Camellia Eshoa, Christopher R. Chitambar

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.

Original languageEnglish (US)
Pages (from-to)646-648
Number of pages3
JournalJournal of drugs in dermatology : JDD
Issue number6
StatePublished - Jun 2007
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Case reports: efalizumab-associated lymphoproliferative disease.'. Together they form a unique fingerprint.

Cite this